Metanoia Bio, a Los Angeles-based biotechnology company spun out from UCLA, is pioneering a novel approach to preventing and reversing chronic and age-related diseases. Our proprietary platform technology focuses on functional cell regeneration, a process that replaces old, damaged cells with healthy, fully functional ones.

This technology, licensed from Dr. Slavica Tudzarova's UCLA lab, utilizes a unique pharmacological approach to stimulate this natural cell renewal process. We currently target diseases like diabetes, diabetic retinopathy, pancreatic cancer, Alzheimer's disease, and heart failure.

Our proprietary platform technology focuses on functional cell regeneration, a process that replaces old, damaged cells with healthy, fully functional ones.

Our research has identified a key mechanism in the early stages of diabetes (prediabetes) where the body's natural "quality control" system, responsible for removing dysfunctional cells, becomes impaired. This leads to the accumulation of these harmful cells, contributing to disease progression.